Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vincera Pharma Inc (VINC)

Vincera Pharma Inc (VINC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,417
  • Shares Outstanding, K 21,413
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,160 K
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.46
Trade VINC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.34 on 05/14/24
  • Latest Earnings Date 05/16/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +48.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6607 +4.53%
on 04/26/24
0.9942 -30.54%
on 04/24/24
-0.2596 (-27.32%)
since 04/17/24
3-Month
0.6607 +4.53%
on 04/26/24
9.3722 -92.63%
on 03/11/24
-1.1194 (-61.85%)
since 02/16/24
52-Week
0.6100 +13.21%
on 12/19/23
9.3722 -92.63%
on 03/11/24
-0.9494 (-57.89%)
since 05/17/23

Most Recent Stories

More News
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation ...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Provides Key Strategic Update

Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

VIP236 is a first-in-class anticancer agent, optimized using Vincerx’s proprietary modular bioconjugation platform to target aggressive tumors VIP236...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx...

VINC : 0.6906 (-4.08%)
Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual Meeting

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet...

VINC : 0.6906 (-4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 0.7785
2nd Resistance Point 0.7578
1st Resistance Point 0.7242
Last Price 0.6906
1st Support Level 0.6699
2nd Support Level 0.6492
3rd Support Level 0.6156

See More

52-Week High 9.3722
Fibonacci 61.8% 6.0250
Fibonacci 50% 4.9911
Fibonacci 38.2% 3.9572
Last Price 0.6906
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar